|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/dc06-1769
© 2007 by the American Diabetes Association
Clinical Care/Education/Nutrition |
Factors Influencing Glycemic Control in Type 2 Diabetes During Acute- and Maintenance-Phase Treatment of Major Depressive Disorder With Bupropion
1 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri
2 Department of Veterans Affairs Medical Center, St. Louis, Missouri
3 Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
Address correspondence and reprint requests to Patrick J. Lustman, PhD, Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8134, St. Louis, MO 63110. E-mail: lustmanp{at}wustl.edu
OBJECTIVE—Depression management in both short- and longer-term treatment studies has been associated with improvement in glycemic control. We used bupropion hydrochloride (Wellbutrin XL) to determine whether this improvement could be attributed to changes in anthropometrics or diabetes self-care.
RESEARCH DESIGN AND METHODS—Ninety-three patients with type 2 diabetes and major depressive disorder (MDD) received bupropion hydrochloride in a two-phase, open-label treatment trial. Those who completed the acute phase (10 weeks; n = 75) and whose depression remitted (n = 63) continued bupropion at the remission dose and were followed in the maintenance phase (24 weeks) until attrition (n = 8) or relapse of MDD (n = 0). Self-report scales were used to measure depression symptom severity and diabetes self-care behaviors. Body composition and glycemic control were determined using dual-energy X-ray absorptiometry and serial determinations of A1C.
RESULTS—BMI, total fat mass, and A1C decreased and composite diabetes self-care improved over the acute phase (–0.5 kg/m2, –0.7 kg, –0.5%, and +0.4, respectively, P < 0.01 for each), effects that persisted through the maintenance phase for BMI, A1C, and self-care (P 
0.01 for each). Reductions in BMI (B = 0.30, P = 0.01) and depression severity (B = 0.04, P = 0.046) independently predicted lower A1C after acute-phase treatment, whereas only reduction in depression severity (B = 0.08, P = 0.001) predicted A1C over the maintenance interval.
CONCLUSIONS—In the short term, improvement in glycemic control during bupropion treatment is predicted independently by improvements in mood and body composition. Longer-term improvements in glycemic control are predicted primarily by sustained improvement in mood via mechanisms independent of anthropometric and self-care modifications.
Abbreviations: BDI, Beck Depression Inventory • DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. • HDRS, Hamilton Depression Rating Scale • MDD, major depressive disorder • PHQ-9, Patient Health Questionnaire • SDSCA, Summary of Diabetes Self-Care Activities
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Mier, A. Bocanegra-Alonso, D. Zhan, S. Wang, S. M. Stoltz, R. I. Acosta-Gonzalez, and M. A. Zuniga Clinical Depressive Symptoms and Diabetes in a Binational Border Population J Am Board Fam Med, May 1, 2008; 21(3): 223 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Gonzalez, S. A. Safren, E. Cagliero, D. J. Wexler, L. Delahanty, E. Wittenberg, M. A. Blais, J. B. Meigs, and R. W. Grant Depression, Self-Care, and Medication Adherence in Type 2 Diabetes: Relationships across the full range of symptom severity Diabetes Care, September 1, 2007; 30(9): 2222 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Lustman and R. E. Clouse Depression in Diabetes: The Chicken or the Egg? Psychosom Med, May 1, 2007; 69(4): 297 - 299. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |